PUBLICATION AND RESOURCES

PUBLICATIONS

5.30.2019 | JCO Precision Oncology
Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer

Using nonenrichment-based, potentially more sensitive Epic Sciences circulating tumor cell (CTC) platform, we sought to detect and characterize CTCs in untreated, high-risk localized prostate cancer and to evaluate their clinical implication.
3.20.2019 | Science Translational Medicine
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer

Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Science Translational Medicine 20 Mar 2019. DOI: 10.1126/scitranslmed.aav0891
3.15.2019 | Journal of Clinical Oncology
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study

Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. Published online March 13, 2019. DOI: 10.1200/JCO.18.01731 Journal of Clinical Oncology.
7.5.2018 | JAMA Oncology
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer
Autio KA, Dreicer R, Anderson J, et al. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. JAMA Oncology. Advance Online Publication 2018 July. DOI:10.1001/jamaoncol.2018.2168
FULL PUBLICATION LIST

Resources

SCIENTIFIC POSTERS

6.10.2019
A phase 2 trial in progress: PAMIPARIB, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer and a circulating tumor cell homologous recombination deficiency phenotype or BRCA defects.
6.10.2019
Examination of the additive value of CTC biomarkers of Heterogeneity (Het) and Chromosomal Instability to Nuclear localized ( nl ) AR V7+ CTCs in prediction of poor outcomes to Androgen Receptor signaling inhibitor (ARSi) in Metastatic Castration Resistant Prostate Cancer (mCRPC).
6.10.2019
CTC vs. biopsy tissue sequencing: a concordance analysis of genomic copy number profile from mCRPC patients (pts).
4.19.2019
Simultaneous quantification of activated immune cells and PD-L1 expressing circulating tumor cells (CTCs) in peripheral blood of cancer patients receiving checkpoint inhibitor therapy.
All SCIENTIFIC POSTERS

PACKAGE INSERTS

English CE Mark Blood Collection Kit Package Insert
French CE Mark Blood Collection Kit Package Insert
German CE Mark Blood Collection Kit Package Insert
Spanish CE Mark Blood Collection Kit Package Insert
ALL INSERTS

EPIC PODCAST: FEATURED

6.13.2019
EPISODE 02 | LAUREN LEIMAN

In Episode 2 of Innovations in Cancer, we speak with Lauren Leiman, executive director at BloodPAC, the Blood Profiling Atlas in Cancer (BloodPAC) Consortium, launched October 2017, to accelerate the development and validation of liquid biopsy assays to improve the outcomes of patients with cancer. Lauren discusses the collaborative infrastructure that enables sharing of information between stakeholders in industry, academia, and regulatory agencies with the goal to standardize liquid biopsies to improve outcomes for patients.

Listen Now
MORE EPISODES